Kephera Diagnostics LLC
Framingham, MA
- UEI
- LJFNSE6NM648
- CAGE
- 7RVB8
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1 Grant St #300, Framingham, MA 01702, USA
- Website
- kephera.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Rapid diagnostic immunoassay for strongyloidiasis - abstract strongyloidiasis, caused by the parasitic nematode… | National Institute of Allergy and Infectious Diseases | $303,250 | |
| Peptide-based elisa for laboratory diagnosis of sarcoidosis - project summary sarcoidosis is a systemic inflammatory… | National Heart Lung and Blood Institute | $470,013 | |
| Novel diagnostic biomarkers discovery and validation for malaria and select neglected tropical diseases sbir phase i | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Micria: two-minute rapid assay platform for point-of-care diagnosis | Office of Financial Resources | $909,750 | |
| Sbir 133 - kephera | National Institute of Allergy and Infectious Diseases | $300,000 |
About Kephera Diagnostics LLC
Kephera Diagnostics LLC is a for-profit limited liability company headquartered in Framingham, Massachusetts, specializing in developing innovative diagnostic solutions for infectious diseases, with a particular focus on neglected tropical diseases and parasitic infections. The company is registered in SAM.gov and provides advanced diagnostic technologies and research services to federal agencies, leveraging its expertise in creating specialized in vitro diagnostic tests and biomarker-based screening technologies to address critical global health challenges.
Through federal contract awards, Kephera Diagnostics has secured multiple Small Business Innovation Research (SBIR) contracts primarily from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI). These contracts, ranging from $300,000 to $1,999,961, are predominantly set aside for small businesses and focus on developing diagnostic technologies for specific infectious diseases. Notable contract projects include developing diagnostic tests for liver flukes (Opisthorchis viverrini and Clonorchis sinensis), creating a biomarker-based test of cure for Chagas infection, and researching novel diagnostic biomarkers for malaria and select neglected tropical diseases. The contracts typically involve early-stage research and development efforts, with completion dates ranging from 2022 to 2026.
The federal grant awards received by Kephera Diagnostics demonstrate a comprehensive approach to diagnostic research across various infectious and inflammatory diseases. Grants from the National Institutes of Health (NIH) and the Office of the Director support projects such as developing a peptide-based ELISA diagnostic test for sarcoidosis, creating a point-of-care diagnostic platform called MICRIA, and designing diagnostic assays for congenital Chagas disease and human hookworm infections. These grant-funded projects aim to address critical diagnostic challenges in diseases with limited current testing capabilities, focusing on developing innovative, accessible, and accurate diagnostic technologies. The grant awards range from developing serosurveillance tools to creating mobile phone-compatible diagnostic solutions, with award periods typically spanning two to three years and funding amounts around $300,000 to $508,178.
SBA capabilities narrative
Research and Development of diagnostic assays for infectious diseases and pathogens, including viral, bacterial and parasitic diseases, including COVID-19.
Quick answers
What is Kephera Diagnostics LLC's UEI?
Kephera Diagnostics LLC's Unique Entity ID (UEI) in SAM.gov is LJFNSE6NM648.
What is Kephera Diagnostics LLC's CAGE code?
Kephera Diagnostics LLC's CAGE code is 7RVB8.
What is Kephera Diagnostics LLC's primary NAICS code?
Kephera Diagnostics LLC's primary NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing).
Where is Kephera Diagnostics LLC located?
Kephera Diagnostics LLC's physical address in SAM.gov is 1 Grant St #300, Framingham, MA 01702, USA.
Is Kephera Diagnostics LLC registered in SAM.gov?
Yes. Kephera Diagnostics LLC's SAM.gov registration is active through February 18, 2027.
What is Kephera Diagnostics LLC's most recent federal award?
Kephera Diagnostics LLC's most recent federal grant award is Rapid diagnostic immunoassay for strongyloidiasis - abstract strongyloidiasis, caused by the parasitic nematode… (R43AI186917), from National Institute of Allergy and Infectious Diseases, on August 24, 2026.
On GovTribe
See Kephera Diagnostics LLC's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors